Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection
Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
4
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
1
trials recruiting
5
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520
Clinical Trials (5)
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
A Phase Ⅱ Study of F520 in Patients With Cervical Carcinoma
PD-1 Inhibitor and Nab-paclitaxel and Bevacizumab in CUP
Phase Ⅰ Study to Evaluate the Safety and Tolerability of Using F520
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5